News Archives - Page 261 of 612

ThursdaySep 09, 2021 11:21 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021 Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13 Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases with high unmet medical needs, such as chronic pain conditions and eating disorders As a company at the forefront of the psychedelic renaissance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has differentiated itself…

WednesdaySep 08, 2021 2:49 pm

Simply Sonoma Inc. Offering Organic CBD Alternatives to Traditional Manufactured Products

Company is committed to providing products based on formulations driven by solid scientific research Simply Sonoma is creating three tiers of products The company is developing products in four areas: the sleep aid market, the pain and inflammation sectors, the probiotic space, and the beauty and skin segments In a CBD market becoming ever more crowded, Simply Sonoma is preparing to launch a line of CBD products that is truly distinctive. The company, which is also in the midst of a SEC regulation CF offering, is creating unique medicinal hemp strains that are alternatives to traditional, chemically manufactured offerings. Specifically,…

WednesdaySep 08, 2021 12:04 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on Monday, Sept. 13, 2021. Interested institutional or retail investors should visit https://ibn.fm/VL1jk to register for the conference and may listen to the company’s presentation online at https://ibn.fm/YuFWj. A replay of the presentation will be available via the Investor Relations page of the company’s website. To…

WednesdaySep 08, 2021 10:00 am

Tingo Inc. (IWBB) Is ‘One to Watch’

Investor appetite in Africa continues to be robust, attracting $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018 Agriculture makes up 23 percent of sub-Saharan Africa’s GDP and 60 percent of employment Tingo directly benefits the African economy by helping farmers gain better prices for their crops The company enables more efficient markets via greater distribution of agricultural products Tingo directly provides an access point to technology for tens of millions of Africans The company is expanding into fintech banking services for the mass market, providing access to financial services through Tingo Pay, its proprietary mobile wallet application…

WednesdaySep 08, 2021 9:30 am

Ideanomics Inc. (NASDAQ: IDEX) Completes Commercial EV Ecosystem Reach through M&A Deal with Van Manufacturer VIA

Sustainability cultivator Ideanomics has reached an agreement with commercial EV vehicle manufacturer VIA Motors to acquire VIA in an all-stock transaction valued at $450 million The VIA acquisition will solidify Ideanomics’ position as a made-in-America brand focused on building an end-to-end commercial EV ecosystem Ideanomics has completed other M&A activity in recent months designed to establish sustainable solutions that reduce the harmful effects of pollutants on the earth’s climate, particularly involving wireless battery-charging technology for commercial fleets The acquisition will help VIA to focus on completing the manufacturing process, with vehicles expected to roll out by 2023 New York-based Ideanomics…

WednesdaySep 08, 2021 9:30 am

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021 The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China A recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world and 1st in China for the number of clinical samples analyzed amongst companies that offer next-generation early cancer screening and detection technology AnPac Bio-Medical Science (NASDAQ: ANPC) recently held its 2021 technical symposium…

WednesdaySep 08, 2021 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology

Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since January 2017 The technology is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions DehydraTECH-enabled drugs offer multiple benefits, including faster delivery, increased bioavailability, increased brain absorption, improved drug…

WednesdaySep 08, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible…

WednesdaySep 08, 2021 9:00 am

AmpliTech Group Inc. (NASDAQ: AMPG) Highlights from First Six Months of 2021

AmpliTech posted $1,024,410 in total revenue for Q2’21, a 55% increase from the same period in 2020 It also announced having paid off $1 million in debt while securing $0.2 million in SBA loan forgiveness The company also purchased $0.4 million worth of scientific equipment to enhance product development and testing The first half of 2021 also saw AmpliTech complete its financial recapitalization and Nasdaq up-listing, thereby realizing a working capital of $29.8 million All these achievements are positioning AmpliTech as the key infrastructure provider that supports 5G, satellite and other radio frequency communications infrastructure globally On August 16, 2021,…

Site Search

Company Search

Category: News

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Simply Sonoma Inc. Offering Organic CBD Alternatives to Traditional Manufactured Products

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Tingo Inc. (IWBB) Is ‘One to Watch’

Ideanomics Inc. (NASDAQ: IDEX) Completes Commercial EV Ecosystem Reach through M&A Deal with Van Manufacturer VIA

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

AmpliTech Group Inc. (NASDAQ: AMPG) Highlights from First Six Months of 2021

Market Basics

Newsletter Publishers

Public Companies